ライフサイエンスコーパス: side effect

1 -to-moderate severity) being the most common side effect.

2 al tumors, but intestinal injury is a common side effect.

3 DOR) produces similar analgesia with reduced side effects.

4 ilies to analyse their association with drug side effects.

5 e potential to decrease chemotherapy-related side effects.

6 aminase free, suggesting it would have fewer side effects.

7 m include potential induction of significant side effects.

8 apeutic effect with reduced off-target toxic side effects.

9 apachone treatment in humans, avoiding toxic side effects.

10 ence compromises immunity, leading to severe side effects.

11 for improving drug efficacy while mitigating side effects.

12 CCA growth in vivo without inducing obvious side effects.

13 so shown beneficial effect, without unwanted side effects.

14 er, it requires doses that cause significant side effects.

15 presence and severity of treatment-emergent side effects.

16 -brain-barrier (BBB) and eliminates systemic side effects.

17 ism that impact therapeutic action and toxic side effects.

18 ogenous contrast agents, avoiding associated side effects.

19 wise required would likely have unacceptable side effects.

20 y to be within proteins associated with drug side effects.

21 on designed to forego central and intestinal side effects.

22 nes is still impeded by their multiple toxic side effects.

23 offers further protection but has additional side effects.

24 enhance the therapeutic benefits and reduce side effects.

25 ering for better tumor targeting and reduced side effects.

26 nd to disclose their therapeutic profiles or side effects.

27 oms; quality of life; functioning; and major side effects.

28 es, and poor selectivity along with unwanted side effects.

29 r or ARMD treatment in order to avoid ocular side effects.

30 drug development to eliminate their unwanted side effects.

31 m use of opioids is associated with multiple side effects.

32 properties of opioids from their undesirable side effects.

33 hat maximised efficacy and minimised adverse side effects.

34 ed use of glucocorticoids is associated with side effects.

35 lve infectious inflammation without unwanted side effects.

36 on, which could potentially reduce cognitive side effects.

37 r cells in vivo, without causing significant side effects.

38 awake DBS may lead to less treatment-induced side effects.

39 th abuse potential or drugs with undesirable side effects.

40 em level are accompanied by some detrimental side effects.

41 of patients and is associated with frequent side effects.

42 en to be safe, with a relatively low rate of side effects.

43 GF has not fulfilled its full potential with side effects.

44 achieve better longterm outcomes with fewer side effects.

45 rties, which are confounded with significant side effects.

46 ude use of these agents with their potential side effects.

47 apy, with severe and noncharacterized ocular side effects.

48 to increase efficacy and/or reduce undesired side effects.

49 ee left for reasons related to anxiety about side effects.

50 k selectivity for the MC1R and thus can have side effects.

51 y of treatment with no visible recurrence or side effects.

52 ssesses limitations related to dose limiting side effects.

53 s by the antibiotics and elucidate potential side effects.

54 therapy and to minimize stimulation-induced side effects.

55 eness to dobutamine is limited with numerous side effects.

56 ic, and does not seem to possess emetic-like side effects.

57 because of a lack of efficacy or intolerable side effects.

58 o treat cancer despite severe energy balance side effects.

59 of scopolamine, its mechanisms of action and side effects.

60 ter treatment cessation, and minimization of side effects.

61 ient's metabolism, a key condition to reduce side effects.

62 drug, enhance efficacy, and reduce unwanted side effects.

63 or designing effective treatments with fewer side effects.

64 ce in the target population with no reported side effects.

65 erapeutic benefits are compromised by severe side effects.

66 atment leads to a wide range of debilitating side effects.

67 ions, such as low bioavailability and severe side effects.

68 f bleaching and decrease the severity of its side effects.

69 -sensitizing efficacy as TZDs, but lack many side effects.

70 erved in the absence of significant sedative side effects.

71 capacity of beta-cells, is linked to adverse side effects.

72 onal contraceptive and to identify long-term side-effects.

73 in, due to its vitamin-like profile, has few side-effects.

74 e of treatment should be guided primarily by side-effects.

75 nts suffer from persistent treatment-related side-effects.

76 h of exaggerated claims about statin-related side-effects.

77 tibiotic use, length of stay, and antibiotic side-effects.

78 fic adherence and coverage, and symptoms and side-effects.

79 .0001) and a reduction in antibiotic-related side-effects (16% vs 22%, adjusted OR 0.68 [95% CI 0.57

80 nt a heightened vigilance for early and late side effects, a priori because real-life patients can be

81 imeric antigen receptor (CAR) may reduce the side effects and augment antitumor activity.

82 including biomedicine, thus their potential side effects and corresponding improvement strategy dese

83 eability from drug clinical phenotypes (drug side effects and drug indications).

84 f high doses of antibiotics, which result in side effects and drug resistance.

85 wever, the high costs of drug design, severe side effects and HCV resistance presented by the existin

86 treatment modality due to its remarkably low side effects and high treatment efficacy compared to con

87 novel anticancer agents that have decreased side effects and increased safety.

88 ate concentrations ratio and extracted their side effects and indications as features.

89 As abundant information on drug side effects and indications has been recorded over time

90 ts systemic use is restricted by its serious side effects and limited efficacy due to activation of T

91 ne or a few indications, their unanticipated side effects and off-label use have contributed signific

92 dvanced to clinical use because of potential side effects and other factors.

93 ection and nasal spray such as pain, adverse side effects and poor bioavailability, a new approach is

94 matory diseases, but suffer from significant side effects and poor responsiveness in certain patient

95 ter selectivity towards tumor cells, reduced side effects and possibility of repeatable treatment.

96 significantly decrease undesirable systemic side effects and reduce required therapeutic dosage.

97 greatly improves our understanding of opioid side effects and suggests intriguing therapeutic approac

98 Relapse, untreated psychosis, intolerable side effects and the lack of effective treatment for neg

99 cs exhibit limitations in efficacy, unwanted side effects and the potential for drug abuse and divers

100 ugs that induce ROS are associated with many side effects and unpleasant symptoms.

101 e in blood pressure, but was devoid of major side effects and was also associated with a small reduct

102 ons, and cardiovascular disease with reduced side effects and will open new doors toward the treatmen

103 fect (even when DNA is the dominant target), side-effects and are implicit in drug resistance.

104 to develop new drugs that do not cause these side-effects and have prolonged anabolic effects on bone

105 and steroids can have undesirable long-term side-effects and lack efficacy in some resistant patient

106 y-expressed pathways, leading to significant side-effects and poor long-term allograft outcomes.

107 tion, pressor effects, other physiologic and side effects, and adverse events.

108 inal motility, be triggerable to address any side effects, and be drug loadable and release drug over

109 ally effective, they may produce undesirable side effects, and provide only partial amelioration of n

110 intervals, peripheral vasodilation, unwanted side effects, and restricted use in pediatric patients.

111 th atropine 0.5%, 0.87+/-0.52 D/year), fewer side effects, and similar long-term results for myopic p

112 cellular components, pharmacologic classes, side effects, and symptoms.

113 ly on a few drugs, most of which have severe side effects, and their helpfulness is being seriously c

114 these medications are associated with severe side effects, and whether they are efficacious in treatm

115 y infections reduces antibiotic exposure and side-effects, and improves survival.

116 and neck cancer can be associated with many side-effects, and many patients suffer from persistent t

117 ymptom control, risk factors, comorbidities, side-effects, and patient satisfaction by means of share

118 Polyphenol metabolism and possible toxic side effects are also considered.

119 isms underpinning antipsychotic efficacy and side effects are poorly understood.

120 mportance in life sciences but light-induced side effects are serious confounding factors.

121 regimens with reduced pill burden and fewer side-effects are desirable for people living with HIV.

122 cantly greater decrease in treatment-related side effects as measured by the UPDRS IV off medication

123 pine efficacy, but still experience the same side-effects as more severely ill patients.

124 r from undesirable psychotropic and sedative side effects, as well as abuse potential.

125 r in vitro study of both the efficacy of and side effects associated with candidate drugs.

126 in the daily diet could also prevent various side effects associated with consumption of excess free

127 r replacement of Taxol(R) that mitigates the side effects associated with Cremophor EL.

128 nd significantly reduces clinically relevant side effects associated with HSC transplantation includi

129 ministration of soluble gp130 to prevent the side effects associated with IL-6 trans-signaling.

130 steric binders may overcome the beta-catenin side effects associated with strong GSK-3beta inhibition

131 ingle medication is unsuccessful or produces side effects at higher dosages; (3) treatment should be

132 patients (15.4%) withdrew due to subjective side-effects at first dose.

133 contributing to better outcomes with a lower side effect burden than standard care.

134 ptor interactions, which can cause dangerous side effects by inhibiting the receptors that are not in

135 e, especially to prevent potential long term side effects by tissue and cellular accumulation.

136 Photoimmunotherapy (PIT) is an emerging low side effect cancer therapy based on a monoclonal antibod

137 tailored on an individual basis, considering side effects, comorbidities, and levels of peripheral an

138 toma via induction of Fas and Fas-L, with no side effects compared to free PTX or temozolomide.

139 s with no evident increased risk of systemic side effects compared with regional corticosteroid thera

140 T to measure binding kinetics, and show that side effects correlate with drug association rates to th

141 It appears possible that anxiety related to side effects could be a factor affecting dropout from SL

142 However, potentially life-threatening side effects decrease the safety and effectiveness of th

143 the clinic, long-term use leads to numerous side effects, driving the need for new and improved drug

144 actor, but its inhibition is associated with side effects due to its pleiotropic roles.

145 petitors and, therefore, are known to elicit side effects due to lack of specificity.

146 Allergic side effects during E-OIT were common but all were mild

147 tios that predict a significant reduction in side effects during therapy.

148 e associated with increased potential ocular side effects (e.g., elevated intraocular pressure, catar

149 in motor functions and explains some of the side effects elicited by D2R blockers when used in neuro

150 hypothesized to show reduced extrapyramidal side effects (EPS) due to their rapid dissociation from

151 neuropathy (CIPN) is a common dose-limiting side effect experienced by patients receiving treatment

152 on the psychotropic medications prescribed, side effects experienced, metabolic outcomes, and scores

153 regarding optimal performance and unforeseen side effects following device implantation into the brai

154 daches and nervousness have been reported as side effects following prolonged Aldara use.

155 used for its psychotropic and mind-altering side effects for millennia.

156 enefit in patients who had already developed side effects from their long-term use of L-dopa revealed

157 pectively (both p<0.0001), and there were no side-effects from either regimen.

158 ceptors are suitable drug targets with fewer side effects, greater therapeutic selectivity, and enhan

159 ping opioid treatments for pain with reduced side effects have focused on the signaling cascades of t

160 sidered promising as an additive to minimize side effects in bleaching gel formulation.

161 d efficacy of BTZ in MM cells and reduce the side effects in healthy tissue.

162 e coadministered with chemotherapy to manage side effects in LSCC patients, so we evaluated whether t

163 lack of selectivity for GR leads to unwanted side effects in some patients.

164 o gauge immunosuppressive medication-related side effects in the absence of a stomach.

165 improving therapeutic efficacy and reducing side effects in vivo.

166 PPIs may have unwanted side effects in vulnerable populations.

167 st prostate cancer cells, with minimal toxic side-effects in vivo Structural optimization based on st

168 while minimizing or eliminating carcinogenic side effects.In this study, we sought to determine the b

169 lgesics but their clinical use is limited by side effects including analgesic tolerance and opioid-in

170 Opioid pain medications have detrimental side effects including analgesic tolerance and opioid-in

171 include patient selection, cost, and risk of side effects including angioedema and Alzheimer's diseas

172 r time, however, its efficacy decreases, and side effects including l-DOPA-induced dyskinesia (LID) i

173 TRUS-biopsy can cause side-effects including bleeding, pain, and infection.

174 Potential relevant side effects, including increased risk of drug interacti

175 cancer therapy but which causes a number of side effects, including male infertility.

176 tion of sulfur dioxide, which has well-known side effects, increased the content of certain bioactive

177 systemic administration of drugs, which as a side effect inhibit the transporter.

178 The prediction of this side effect is however challenging as it usually develop

179 This side effect is thought to be mediated by free iodide in

180 program, weighed against potential unwanted side effects is favourable.

181 ect are reviewed, and a brief summary of its side effects is outlined.

182 anding of the neurobiological basis of these side effects is still very limited.

183 One of its major side effects is the increased risk of diabetes mellitus;

184 Side effects lead to therapy discontinuation in 32%.

185 rogression, frequent changes in symptoms and side-effects, led to a complex web of roles and behaviou

186 e in all the patients and often cause severe side-effects, limiting their widespread therapeutic use.

187 ance during GDC-0449 treatment with numerous side effects limits its use.

188 r the treatment of obesity, causes important side effects mainly related to subtype selectivity.

189 ely cause adverse neurological or peripheral side effects, making GRM3 an attractive and specific mol

190 tion to analgesia and related medicines (for side-effect management) in order to describe, characteri

191 rgical option, but both short- and long-term side effects may occur.

192 Extrapyramidal side effects (n = 7) emerged at a threshold concentratio

193 ween putative benefit and potential unwanted side effects needs to be considered.

194 rticles abrogate acute and chronic metabolic side effects normally observed after BYL719 treatment.

195 Thrombocytopenia is a major side effect of a new class of anticancer agents that tar

196 y (CIPN), the most common treatment-limiting side effect of all the most common anticancer therapies.

197 ystemic and neurological diseases, or be the side effect of certain drugs.

198 ourse of antibiotics, which has the unwanted side effect of depleting commensal bacteria.

199 ripheral neuropathy (CIPN) is a debilitating side effect of many cancer treatments.

200 ning ventricular arrhythmias, is a potential side effect of many marketed and withdrawn medications.

201 n (CIPN) is a common and severe debilitating side effect of many widely used cytostatics.

202 Postoperative pain is a potential adverse side effect of oral surgeries, and attempts should be ma

203 its animal reservoirs, with the evolutionary side effect of potential persistence in incidental human

204 herapeutic effects of Tecfidera and its rare side effect of progressive multifocal leukoencephalopath

205 pulmonary fibrosis (RIPF) is a debilitating side effect of radiation therapy (RT) of several cancers

206 Radiation-induced skin injury is a common side effect of radiotherapy and can limit the duration a

207 Nephrotoxicity side effect of the immunosuppressive drug, cyclosporine

208 f thyroid iodide uptake is a well-documented side effect of the use of iodinated contrast media (ICM)

209 e was similar to eczema vaccinatum, a severe side effect of VACV vaccination that may develop in huma

210 With the aim of reducing side effects of acetylcholinesterase inhibitors (AChEIs)

211 ool for predicting therapy responsiveness or side effects of anti-TNF therapy.

212 and contributes to many of the known adverse side effects of ATRA treatment, including skin irritatio

213 re promising cancer therapies, yet prominent side effects of BETi at effective doses have been report

214 In patients with advanced CKD, the side effects of corticosteroids increase, and the renal

215 Given the limited side effects of CQ, its lack of contraindications in pre

216 sex differences in mood disorders and of the side effects of cytochrome P450 aromatase inhibitors, wh

217 ensitization can reduce the dose and adverse side effects of diverse medical treatments which require

218 ysicians and patients sheds new light on the side effects of drugs.

219 nding could have therapeutic implications as side effects of Flunarizine are low and specific sepsis

220 ay be related to the lack of psychotomimetic side effects of GLYX-13 compared with ketamine, whereas

221 ant effects, but without the psychotomimetic side effects of ketamine.

222 hich contribute to the harmful environmental side effects of large-scale agriculture.

223 ge in recognizing and managing the potential side effects of present-day treatment regimens is theref

224 s and 2) prevention of rejection without the side effects of systemic immunosuppression.

225 ng in phase I trials from the dose-dependent side effects of this class of epigenetic therapy.

226 Side effects of this protein kinase inhibitor (PKI) incl

227 onitis and fibrosis constitute dose-limiting side effects of thorax and whole body irradiation.

228 les in clearing the carcass of bacteria as a side-effect of grazing on the carrion.

229 le therapeutic strategy to limit this common side-effect of many types of chemotherapy.

230 Opioid-induced constipation is a frequent side-effect of opioid treatment, and standard interventi

231 ese remarkable advances, concerns about rare side-effects of anti-resorptive drugs, particularly bisp

232 ceptors may account for distinct effects and side-effects of GABAergic agents.

233 d at 24 months, number of cholecystectomies, side-effects of UDCA and quality of life.

234 y biomarker discovery, and possibly the many-sided effects of senescence-associated secretory phenoty

235 children has been suggested for its reduced side effects on behavior.

236 ther cancers is severely hampered by serious side effects on healthy organs.

237 incompatibility with existing GAL4 lines and side effects on physiology and behavior.

238 ter oral administration in addition to other side effects on the gastrointestinal tract, liver and mu

239 nd in a reversible manner without detectable side effects on the lifespan or behavior of the animal.

240 ts multifaceted activity pattern and complex side effects prevent its clinical use.

241 wever, low overall success rates and intense side effects prevent such approaches from being employed

242 This is facilitated by the predicted low side effect profile as the high concentrations of ATP re

243 iluzole was generally well tolerated, with a side effect profile consistent with its clinical use.

244 mal survival while demonstrating a favorable side effect profile.

245 KEYNOTE-001 trial was to assess the safety, side-effect profile, and antitumour activity of pembroli

246 Safety, the side-effect profile, and pharmacodynamic measures (PCSK9

247 The main end points were safety, side-effect profile, pharmacokinetic and pharmacodynamic

248 tution inflammatory syndrome (IRIS), and the side-effect profile.

249 onse rate, overall survival, safety, and the side-effect profile.

250 s problem of drug resistance and the adverse side effect profiles of many TB drugs, further investiga

251 These drugs vary in their efficacy and side-effect profiles but all provide greater weight loss

252 ta-analysis of the consistency, efficacy and side effect rate of lesional treatments for tremor are p

253 atment sessions had to be interrupted due to side effects related to the procedure.

254 ld fears relating to opioids, and experience side effects related to their use.

255 outcome), as well as treatment response and side effects (secondary outcomes) with three acute-phase

256 uropsychiatric Inventory) and extrapyramidal side effects (Simpson Angus Scale scores > 3).

257 but their use is curtailed by dose-limiting side effects such as hyperglycaemia.

258 is challenging and can result in undesirable side effects such as non-specific adsorption, protein de

259 rmulation falls short of expectations due to side effects such as peripheral neuropathy, hypotension,

260 analgesia in inflamed rat paws without major side effects such as sedation or constipation.

261 ay's pharmacopeia can cause serious unwanted side effects, such as immune suppression.

262 tics are indicated because it displays fewer side effects, such as sedation and depression-like sympt

263 ociated with motor and non-motor behavioural side-effects, such as dyskinesias and impulse control di

264 s often accompanied by severe immune-related side effects, suggesting the importance of co-inhibitory

265 To circumvent systemic side effects, targeting peripheral opioid receptors is a

266 form, is associated with fewer unacceptable side effects than amphotericin, and is widely used in pl

267 ent can evoke substantial skin irritation, a side effect that remains poorly understood.

268 supplementation might help reduce the severe side effects that arise from BETi therapy by reducing th

269 rs of PERK's kinase activity cause on-target side effects that have precluded their further developme

270 current cooling strategies cause undesirable side effects that limit their clinical applications.

271 e modestly effective and are associated with side effects that preclude effective dosing in many pati

272 lpha checkpoint inhibitors and the potential side effects that these may have are discussed.

273 applied in patients experiencing intolerable side effects that they attribute to statins.

274 argely relies on prior information including side effects, therapeutic indication, and chemoinformati

275 despread use is constrained by dose-limiting side effects thought to be due to activation of the pero

276 Ten patients reported side-effects (three of whom discontinued the study): ear

277 ictions for both therapeutic indications and side-effects through the published literature.

278 ajor limitation to the use of aspirin is its side effect to cause ulceration and bleeding in the gast

279 ent, but the treatment can cause significant side effects to patients.

280 experiencing any of 21 common antipsychotic side effects, vital signs were obtained, fasting blood s

281 No side effect was recorded.

282 lity to take tolvaptan without dose-limiting side effects was assessed, 1370 patients with ADPKD who

283 Discontinuation of therapy due to side effects was significantly more frequent in the INH

284 Prevalence of IS-related side effects was similar in groups A and B, occurring pr

285 To minimize the side effects, we developed a novel microneedle array (MN

286 stemic ROCK inhibition causes cardiovascular side effects, we evaluated the effects of a locally acti

287 Rates of discontinuation owing to side effects were 35% for INH, 21% for RIF, and 10% for

288 The most serious side effects were exacerbation of left ventricular failu

289 Rates of discontinuation due to side effects were lower among those taking RPT/INH.

290 No side effects were observed.

291 No short-term side effects were observed.

292 Acceptance, completion rates, and side effects were reported for each regimen.

293 No side effects were seen in any patient after (18)F-MFBG i

294 Side effects were short-lived, and clinical improvement

295 Side-effects were uncommon.

296 ne rebound activity and one gastrointestinal side effect) were registered and almost 80% of the patie

297 y, and some patients show paradoxical immune side effects, which are poorly understood.

298 tients and discuss the possible benefits and side effects with them.

299 y detectable epithelial toxicity or systemic side effects with very low drug levels measured in the a

300 c C-terminal regions of the MOR can modulate side effects without altering analgesia.